ATE196507T1 - Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle - Google Patents
Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelleInfo
- Publication number
- ATE196507T1 ATE196507T1 AT95941755T AT95941755T ATE196507T1 AT E196507 T1 ATE196507 T1 AT E196507T1 AT 95941755 T AT95941755 T AT 95941755T AT 95941755 T AT95941755 T AT 95941755T AT E196507 T1 ATE196507 T1 AT E196507T1
- Authority
- AT
- Austria
- Prior art keywords
- homologous recombination
- viral vectors
- prokaryotic cell
- intermolecular homologous
- producing viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9414470A FR2727689A1 (fr) | 1994-12-01 | 1994-12-01 | Nouveau procede de preparation d'un vecteur viral |
PCT/FR1995/001590 WO1996017070A1 (fr) | 1994-12-01 | 1995-12-01 | Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE196507T1 true ATE196507T1 (de) | 2000-10-15 |
Family
ID=9469390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95941755T ATE196507T1 (de) | 1994-12-01 | 1995-12-01 | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle |
Country Status (13)
Country | Link |
---|---|
US (3) | US6110735A (de) |
EP (1) | EP0742834B9 (de) |
JP (1) | JP3989541B2 (de) |
AT (1) | ATE196507T1 (de) |
AU (1) | AU707208B2 (de) |
CA (1) | CA2182303C (de) |
DE (2) | DE69518910T3 (de) |
DK (1) | DK0742834T4 (de) |
ES (1) | ES2150595T5 (de) |
FR (1) | FR2727689A1 (de) |
GR (1) | GR3035050T3 (de) |
PT (1) | PT742834E (de) |
WO (1) | WO1996017070A1 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2727689A1 (fr) * | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
FR2730504B1 (fr) * | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
US6720140B1 (en) * | 1995-06-07 | 2004-04-13 | Invitrogen Corporation | Recombinational cloning using engineered recombination sites |
US6143557A (en) * | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
FR2761689B1 (fr) | 1997-04-02 | 1999-06-25 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
WO1998056937A2 (en) | 1997-06-09 | 1998-12-17 | Genvec, Inc. | Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
AU749856B2 (en) | 1997-09-23 | 2002-07-04 | Genvec, Inc. | Plasmids for construction of eukaryotic viral vectors |
CA2307016A1 (en) * | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
CN101125873A (zh) * | 1997-10-24 | 2008-02-20 | 茵维特罗根公司 | 利用具重组位点的核酸进行重组克隆 |
US5922576A (en) * | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
NZ525134A (en) | 1999-03-02 | 2004-09-24 | Invitrogen Corp | Compositions and methods for use in recombinational cloning of nucleic acids |
EP1248851A2 (de) * | 1999-12-07 | 2002-10-16 | Genethon III | Fuer den transfer in zielzellen bestimmte vektoren, die von dem genom von hunde-adenoviren abgeleitet sind |
EP2210948A3 (de) * | 1999-12-10 | 2010-10-06 | Life Technologies Corporation | Verwendung von mehrfachen Rekombinationsstellen mit einzigartiger Spezifizität beim Rekombinationsklonen |
AU2001283377B2 (en) | 2000-08-14 | 2007-09-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced homologous recombination mediated by lambda recombination proteins |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
GB0027501D0 (en) * | 2000-11-10 | 2000-12-27 | Astrazeneca Ab | Vector |
AU2002212507A1 (en) * | 2000-11-10 | 2002-05-21 | Astrazeneca Ab | Vector |
AU2002361728A1 (en) * | 2001-12-14 | 2003-06-30 | President And Fellows Of Harvard College | Immunocellular receptors related to neurological disorders |
US7521242B2 (en) * | 2003-05-09 | 2009-04-21 | The United States Of America As Represented By The Department Of Health And Human Services | Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids |
BRPI0412279A (pt) * | 2003-07-02 | 2006-09-19 | Diversa Corp | glucanases, ácidos nucléicos codificando as mesmas e métodos para preparar e aplicar os mesmos |
US7790445B2 (en) | 2003-07-21 | 2010-09-07 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
ATE497974T1 (de) | 2003-07-21 | 2011-02-15 | Transgene Sa | Multifunktionelle cytokine |
ATE469984T1 (de) | 2003-12-01 | 2010-06-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
US7674621B2 (en) | 2004-05-21 | 2010-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Plasmids and phages for homologous recombination and methods of use |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
ES2673046T3 (es) * | 2006-09-26 | 2018-06-19 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
CN101617052A (zh) | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | 用于免疫的乳头瘤病毒e2多肽 |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
EP2387414A1 (de) | 2009-01-13 | 2011-11-23 | Transgene SA | Verwendung einer saccharomyces cerevisiae mitochondrialen nukleinsäuren-fraktion zur immunstimulation |
HUE025015T2 (en) | 2009-01-20 | 2016-04-28 | Transgene Sa | Soluble in ICAM-1 as a biomarker for predicting therapeutic response |
KR20110138354A (ko) | 2009-03-24 | 2011-12-27 | 트랜스진 에스.에이. | 환자를 모니터링하기 위한 바이오마커 |
PL2419728T3 (pl) | 2009-04-17 | 2014-05-30 | Transgene Sa | Biomarker do monitorowania pacjentów |
CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
US20110015256A1 (en) * | 2009-07-16 | 2011-01-20 | Ihab Mamdouh Ishak Sadek | Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions |
MX2012001592A (es) | 2009-08-07 | 2012-05-22 | Transgene Sa | Composicion para el tratamiento de la infección del virus de la hepatitis b. |
CA2832307A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
RS58868B1 (sr) | 2012-02-07 | 2019-08-30 | Infectious Disease Res Inst | Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih |
US9555099B2 (en) | 2012-05-16 | 2017-01-31 | Immune Design Corp. | Vaccines for HSV-2 |
EP3587455A1 (de) | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren |
KR102039520B1 (ko) | 2013-04-18 | 2019-11-01 | 이뮨 디자인 코포레이션 | 암 치료에 이용하기 위한 gla 단일요법 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
HUE059605T2 (hu) | 2016-05-16 | 2022-11-28 | Access To Advanced Health Inst | TLR agonista tartalmú készítmény és használati eljárások |
US11173126B2 (en) | 2016-06-01 | 2021-11-16 | Infectious Disease Research Institute | Nanoalum particles comprising a PAA sizing agent |
EP3516064A1 (de) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | Neue promotoren |
MX2019003116A (es) | 2016-09-20 | 2019-08-29 | Boehringer Ingelheim Vetmedica Gmbh | Nueva vacuna contra la gripe porcina. |
EP3515504B1 (de) | 2016-09-20 | 2023-07-12 | Boehringer Ingelheim Vetmedica GmbH | Hundeadenovirus vektor |
US10619169B2 (en) | 2016-09-20 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | EHV insertion site ORF70 |
EP3522920A2 (de) | 2016-10-10 | 2019-08-14 | Transgene SA | Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie |
CN110418650A (zh) | 2016-11-16 | 2019-11-05 | 免疫治疗有限公司 | 用于治疗过敏的核酸 |
CN110799529A (zh) | 2017-04-22 | 2020-02-14 | 免疫治疗有限公司 | 改良lamp构建物 |
US20200087365A1 (en) | 2017-05-02 | 2020-03-19 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising cancer antigens |
JP7339942B2 (ja) | 2017-09-08 | 2023-09-06 | アクセス ツー アドバンスト ヘルス インスティチュート | サポニンを含むリポソーム製剤および使用方法 |
JP2021523185A (ja) | 2018-05-15 | 2021-09-02 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | アレルゲンを含む改善されたlamp構築物 |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
EP4041873A4 (de) | 2019-10-08 | 2023-10-25 | Trustees of Boston College | Proteine, die mehrere verschiedene unnatürliche aminosäuren enthalten, und verfahren zum herstellen und verwenden solcher proteine |
JP2022551732A (ja) | 2019-10-18 | 2022-12-13 | イミュノミック セラピューティックス, インコーポレイテッド | がん抗原を含む改良lamp構築物 |
BR112022009598A2 (pt) | 2019-11-18 | 2022-08-16 | Janssen Biotech Inc | Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
EP4135757A1 (de) | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma- und steap1-impfstoffe und ihre verwendungen |
US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
US20230029453A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
EP4175721A1 (de) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostata-neoantigene und ihre verwendungen |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
FR2727689A1 (fr) * | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
US5582362A (en) * | 1995-03-31 | 1996-12-10 | Johnson; John R. | Center feed toilet paper dispenser |
-
1994
- 1994-12-01 FR FR9414470A patent/FR2727689A1/fr active Granted
-
1995
- 1995-12-01 EP EP95941755A patent/EP0742834B9/de not_active Expired - Lifetime
- 1995-12-01 CA CA002182303A patent/CA2182303C/fr not_active Expired - Lifetime
- 1995-12-01 DK DK95941755T patent/DK0742834T4/da active
- 1995-12-01 AU AU43068/96A patent/AU707208B2/en not_active Expired
- 1995-12-01 WO PCT/FR1995/001590 patent/WO1996017070A1/fr active IP Right Grant
- 1995-12-01 JP JP51834696A patent/JP3989541B2/ja not_active Expired - Lifetime
- 1995-12-01 DE DE69518910T patent/DE69518910T3/de not_active Expired - Lifetime
- 1995-12-01 ES ES95941755T patent/ES2150595T5/es not_active Expired - Lifetime
- 1995-12-01 AT AT95941755T patent/ATE196507T1/de active
- 1995-12-01 DE DE69518910A patent/DE69518910D1/de not_active Expired - Lifetime
- 1995-12-01 PT PT95941755T patent/PT742834E/pt unknown
- 1995-12-01 US US08/682,794 patent/US6110735A/en not_active Expired - Lifetime
-
1999
- 1999-12-21 US US09/467,952 patent/US6281000B1/en not_active Expired - Lifetime
-
2000
- 2000-12-12 GR GR20000402737T patent/GR3035050T3/el unknown
-
2001
- 2001-08-27 US US09/938,491 patent/US7067310B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6110735A (en) | 2000-08-29 |
WO1996017070A1 (fr) | 1996-06-06 |
ES2150595T5 (es) | 2005-12-01 |
ES2150595T3 (es) | 2000-12-01 |
FR2727689B1 (de) | 1997-02-28 |
US6281000B1 (en) | 2001-08-28 |
EP0742834B9 (de) | 2005-12-28 |
US20020090715A1 (en) | 2002-07-11 |
DE69518910D1 (de) | 2000-10-26 |
DK0742834T4 (da) | 2005-08-22 |
DE69518910T3 (de) | 2006-07-13 |
JP3989541B2 (ja) | 2007-10-10 |
AU4306896A (en) | 1996-06-19 |
PT742834E (pt) | 2001-03-30 |
DE69518910T4 (de) | 2006-02-09 |
DE69518910T2 (de) | 2001-03-29 |
US7067310B2 (en) | 2006-06-27 |
CA2182303A1 (fr) | 1996-06-06 |
FR2727689A1 (fr) | 1996-06-07 |
AU707208B2 (en) | 1999-07-08 |
CA2182303C (fr) | 2005-06-21 |
EP0742834B1 (de) | 2000-09-20 |
DK0742834T3 (da) | 2001-01-29 |
EP0742834A1 (de) | 1996-11-20 |
JPH09509330A (ja) | 1997-09-22 |
EP0742834B2 (de) | 2005-08-03 |
GR3035050T3 (en) | 2001-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE196507T1 (de) | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle | |
ATE192500T1 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
CA2020668A1 (en) | Fused or hybrid protein comprising viral antigen and lymphokine | |
CA2102208A1 (en) | Binding domains in notch and delta proteins | |
CA2161808A1 (en) | Bmp-11 compositions | |
EP2278022A3 (de) | Expressionsvektoren, Transfektionssysteme und Verfahren zu deren Verwendung | |
FR2686896B1 (fr) | Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique. | |
MY117686A (en) | Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof | |
AU4880093A (en) | Retrovirus from the HIV group and its use | |
EP2298355A3 (de) | Albuminfusionsproteine | |
ATE188740T1 (de) | Viruspartikel mit veraendertem wirtspektrum | |
NO960309L (no) | Agonister og antagonister for humaninterleukin-10 | |
AU3406595A (en) | Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus | |
DE69841015D1 (de) | Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 | |
AU596997C (en) | Pharmaceutical composition for the treatment of leukopenia | |
AU4826493A (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
ATE2442T1 (de) | Verfahren zur herstellung von interferon und dabei verwendete kulturmediumzusammensetzung. | |
WO1998040498A3 (en) | Immunoadhesins and methods of production and use thereof | |
ATE237691T1 (de) | Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung | |
DE3750348D1 (de) | Verfahren zur Herstellung von Peptiden, dazu zu verwendendes rekombinantes Plasmid und mit diesem Plasmid transformierte Myelomzellen. | |
ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
AUPM772494A0 (en) | Improvements in production of proteins in host cells | |
WO2000006735A8 (en) | Interferon alpha hybrids | |
DE50006815D1 (de) | Verfahren zur herstellung antitumoraler th1-zellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
UEP | Publication of translation of european patent specification |
Ref document number: 0742834 Country of ref document: EP |